| Idiopathic Pulmonary Fibrosis |
1 |
1 |
| Lung Fibrosis |
0 |
0.87 |
| Interstitial Lung Disease |
0 |
0.42 |
| Adverse Effects |
0 |
0.39 |
| Lung |
0 |
0.39 |
| Clinical Research |
0 |
0.2 |
| Grant |
0 |
0.2 |
| Insurance |
0 |
0.2 |
| Medicare |
0 |
0.2 |
| Proteinuria |
0 |
0.2 |
| Quality of Life |
0 |
0.2 |
| Systemic Sclerosis |
0 |
0.2 |
| Thorax |
0 |
0.2 |
| Diarrhea |
0 |
0.17 |
| Patient Safety |
0 |
0.17 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Scleroderma |
0 |
0.09 |
| Toxicology |
0 |
0.09 |